Загрузка...
Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy
Hexamethylene bisacetamide-inducible protein 1 (HEXIM1) is best known as the inhibitor of positive transcription elongation factor b (P-TEFb) and is recently identified as a novel positive regulator of p53. We previously showed the basic region (BR) of HEXIM1 mediates the binding of HEXIM1 to a nucl...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4868700/ https://ncbi.nlm.nih.gov/pubmed/26734838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6794 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|